Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I/II Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

Summary

The purpose of this phase I/II study is to assess the safety of the combination of CORT125134, a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in patients with solid tumors and to determine the preliminary efficacy of the combination of CORT125134 and nab-paclitaxel.

General Information

NCT#: NCT02762981
Study ID: CORT125134-550
Trial Phase: Phase I/II

Trial Sponsor: Corcept Therapeutics
Therapies Used in This Trial: Nab-paclitaxel, CORT125134

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search